Pharma
Pharma·
Russia Plague Death Spotlights Vaccine Gaps and WHO Ineptitude
Pharma·
Bambusa Therapeutics Files for IPO to Finance Eczema Drug Trials
Pharma·
Eli Lilly-Backed TRex Bio Grabs $116.7 Million in IPO — Priced at the Bottom, Still a Win
Pharma·
J&J Skips Obesity, Doubles Down on Cancer and AI Drug Discovery
Pharma·
Tick-Borne Lyme Disease Surges, Drugmakers Race for Vaccines and Blockers
Pharma·
Weight-Loss Drugs May Ease Joint Pain, But They Are No Free Lunch
Pharma·
India's Supreme Court Targets Pharma Sales Tactics — Another Regulatory Hammer Heads for the Industry
Pharma·
Shanghai Allist Plunges 20% as ArriVent Trial Collapse Kills Global Hopes
Pharma·
Russia's Plague Lab Death: Bureaucratic Fog Over a Dead Worker
Pharma·
Merck Loses Keytruda Franchise Protection as European Courts Block Injectable Version
Pharma·
WHO Blocks Obesity Drugs for Kids Under 10 — Bureaucrats Over Parents Again
Pharma·
Eli Lilly-Backed TRex Bio Files for $133.3 Million IPO
Pharma·
Nobel for Optogenetics Hands Investors a New Biotech Frontier
Pharma·
CSL Bets $1.6 Billion on Kidney and Liver Breakthrough
Pharma·
AstraZeneca and Daiichi Sankyo Bet Big on Summit’s China-Bred Cancer Drug
Pharma·
Novartis Bets $7.8 Billion on Chinese mRNA Autoimmune Therapy
Pharma·
Boehringer-Zealand Obesity Drug Falls Short — 13% Weight Loss Misses the Mark
Pharma·
Sanofi and Regeneron Ink $8 Billion Deal — Capital Allocators, Not Bureaucrats, Drive Real Innovation
Pharma·
Lilly Stacks Amylin on Zepbound for 23% Weight Loss — Capital Beats Regulation Again
Pharma·
Lilly's Amylin Combo Pushes Weight Loss to 23%, Side Effects Climb
Pharma·
Lilly Combo Hits 23% Weight Loss — A Market Signal Regulators Should Read
Pharma·
UniQure’s Four-Year Data Exposes the Illusion of Early Gene-Therapy Wins
Pharma·
Novo Nordisk Lands Second Licensing Deal After Market Slap
Pharma·
Novo Nordisk Pays $2.6 Billion for Hengrui Oral Obesity Pill — Investors Should Demand Results, Not More Pipeline Theater
Pharma·
Lilly CEO Signals Bigger Bolt-Ons in the White Spaces
Pharma·
Ozempic Users: Skip the Bureaucracy, Get the Eye Check
Pharma·
Adarx Pharma Jumps 30% on $446M Upsized IPO — Capital Markets Still Work
Pharma·
Novo Nordisk Writes a $1.3B Check to Nanexa for Quarterly GLP-1 Shots
Pharma·
Novo Nordisk Bets $1.3 Billion on Nanexa to Stretch One Shot Across Months
Pharma·